Dr. Amr Hassan is a Consultant Medical Oncologist & Hematologist in Burjeel Hospital, Dubai.
Dr. Amr Hassan did both his fellowship and residency in The University of Massachusetts Medical School. He is a triple board-certified physician by American Board of Internal Medicine in Internal Medicine, Hematology and Medical Oncology with close to 12 years of clinical experience in managing Medical Oncology disorders and Hematologic diseases both benign and malignant.
Dr. Amr Hassan has been involved as a principal investigator and a sub-investigator in multiple clinical trials in the USA. Dr. Amr Hassan uses the latest treatment regimens and protocols in accordance with the American National Comprehensive Cancer Network (NCCN) guidelines. He has been incorporating the latest approved drugs by the American FDA including targeted chemotherapeutic agents and immunotherapy drugs.
Over 12 Years
Dr. Amr Hassan became a certified Medical Doctor after acquiring his Doctor of Medicine degree from Ross University School of Medicine.
Bachelor of Science in Biology and Medical Technology from Framingham State University.
Dr. Amr completed his Residency in Internal Medicine at the University of Massachusetts Memorial Medical Centre, (UMass Medical School).
Dr. Amr completed his Fellowship in Hematology and Medical Oncology at the University of Massachusetts Memorial Medical Center (UMass Medical School).
Board Certificate in Medical Oncology by The American Board of Internal Medicine (ABIM)
Board Certified in Hematology and Internal Medicine by The American Board of Internal Medicine (ABIM)
Medical Technology certification by The American Society for Clinical Pathology (ASCP)
Multi-center, randomized, double-blind phase III trial to evaluate efficiency and safety of B1695502 plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer
A randomized phase 3 trial of the efficacy and safety of Glufosfamide compares with 5-FU in patients with metastatic pancreatic adenocarcinoma previously treated with Gemcitabine
Development of risk- prediction models for chemotherapy-induced febrile neutropenia in patients with breast cancer, colorectal cancer, lung cancer, and non-Hodgkin lymphoma
Prospective, non-interventional study of disease progression and treatment of patients with polycythemia vera in the United States academic and community clinical practices (REAVEL)